DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
FDA Awards UNC Researcher $2M Grant to Study Kidney Disease in Sickle Cell Anemia
The U.S. Food and Drug Administration (FDA) has awarded Dr. Kenneth Ataga, a $2 million grant over five years to support a prospective study in sickle cell anemia to determine biomarkers of specific cellular function changes in chronic kidney disease (CKD).
Ataga, a researcher with the University of North Carolina at Chapel Hill, published the results of a Phase 2 SUSTAIN clinical trial (NCT01895361) in December 2016. The trial demonstrated that the anti-P-selectin antibody crizanlizumab (SEG101), developed by Selexys Pharmaceuticals and Novartis, reduced the median annual rate of sickle cell-related pain crises by 45.3 percent, when compared to placebo.


Related Content
-
news & eventsSiklos®, the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now availab...Medunik USA, a company dedicated to impr...
-
news & eventsMARAC Advisory Statement: Gene Therapy & Bone Marrow TherapiesPlease note: A previous version of this ...
-
education & researchThe State-of-the-Art Methodology Behind New Sickle Cell Disease GuidelinesSickle cell disease (SCD) is an inherite...
-
videos & visualsInfographic: Understanding Sickle Cell Disease – ASHhttps://www.onescdvoice.com/wp-content/u...
-
education & researchOpioid management strategy decreases admissions in high-utilizing adults with sickle cell diseaseBackground: A subset of adults with sic...
-
news & eventsHospitals See No Link Between US Opioid Crisis and Patients’ Use of Treatment, Study ReportsThe U.S. opioid epidemic is not linked t...
-
news & events
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by

This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.